Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:MLNT Melinta Therapeutics (MLNT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Melinta Therapeutics Stock (NASDAQ:MLNT) 30 days 90 days 365 days Advanced Chart Ad Colonial MetalsA “Thank You Gift” From Pres. Trump - GeniusThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Get Melinta Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.35▼$0.5052-Week Range N/AVolumeN/AAverage Volume713,628 shsMarket Capitalization$6.88 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewMelinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens. The company has license agreements with Yale University, Medical Research Council, Wakunaga Pharmaceutical Co., Ltd., and CyDex Pharmaceuticals, Inc. Melinta Therapeutics, Inc. was founded in 2000 and is headquartered in New Haven, Connecticut.Read More… A “Thank You Gift” From Pres. Trump - Genius (Ad)The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Receive MLNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Melinta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MLNT Stock News HeadlinesMelinta Therapeutics Announces IDWeek 2024 Presentations Focused on Melinta’s Portfolio of Commercial and Investigational Stage ProductsOctober 17, 2024 | finance.yahoo.comMelinta Therapeutics Announces the Appointment of Sunitha Lakshminarayanan, as Chief Technology OfficerSeptember 5, 2024 | finance.yahoo.comTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… November 24, 2024 | Crypto 101 Media (Ad)SWTX SpringWorks Therapeutics, Inc.April 23, 2024 | seekingalpha.comFDA Requests Additional Data for Venatorx and Melinta's Antibiotic CombinationFebruary 28, 2024 | msn.comPromising Phase 3 Results for Cefepime-Taniborbactam in Treating Complicated UTIsFebruary 27, 2024 | msn.comVenatorx and Melinta Provide Update on Status of U.S. New Drug Application for Cefepime-TaniborbactamFebruary 23, 2024 | finance.yahoo.comCidara, Melinta announce publication of Rezzayo data in medical journalDecember 5, 2023 | msn.comSee More Headlines MLNT Stock Analysis - Frequently Asked Questions How were Melinta Therapeutics' earnings last quarter? Melinta Therapeutics Inc (NASDAQ:MLNT) announced its earnings results on Tuesday, November, 12th. The biotechnology company reported ($15.67) EPS for the quarter, missing the consensus estimate of ($2.55) by $13.12. The biotechnology company earned $15.87 million during the quarter, compared to analysts' expectations of $15.51 million. Melinta Therapeutics had a negative net margin of 393.39% and a negative trailing twelve-month return on equity of 101.29%. When did Melinta Therapeutics' stock split? Shares of Melinta Therapeutics reverse split before market open on Friday, February 22nd 2019. The 1-5 reverse split was announced on Thursday, February 21st 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 21st 2019. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. What other stocks do shareholders of Melinta Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Melinta Therapeutics investors own include Cara Therapeutics (CARA), Clearside Biomedical (CLSD), Chimerix (CMRX), Aerie Pharmaceuticals (AERI), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY) and Gilead Sciences (GILD). Company Calendar Last Earnings11/12/2019Today11/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:MLNT CUSIP15130J10 CIK1461993 Webwww.melinta.com Phone908-617-1309FaxN/AEmployees290Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($17.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-157,190,000.00 Net Margins-393.39% Pretax MarginN/A Return on Equity-101.29% Return on Assets-28.68% Debt Debt-to-Equity Ratio1.11 Current Ratio1.03 Quick Ratio0.72 Sales & Book Value Annual Sales$96.43 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$16.96 per share Price / BookN/AMiscellaneous Outstanding Shares13,750,000Free FloatN/AMarket Cap$6.88 million OptionableOptionable Beta4.16 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:MLNT) was last updated on 11/24/2024 by MarketBeat.com Staff From Our PartnersThe #1 ETF for monthly incomeWe just found the #1 ETF for monthly income. This outlier is paying a huge 22% dividend... And you could...Investors Alley | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredShocking footage from Bill Gates’ $100,000,000,000 AI BetIf you missed out on Nvidia, watch this video I just made.Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Melinta Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Melinta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.